Panorama emergente dos inibidores do SGLT2 em populações pediátricas com doenças renais: Revisão da literatura
DOI:
https://doi.org/10.25753/BirthGrowthMJ.v33.i2.34096Palavras-chave:
diabetes mellitus, doença cardiovascular, doença renal crónica, gliflozina, inibidor do co-transportador 2 de sódio e glicose, pediatriaResumo
Os inibidores do cotransportador 2 de sódio e glicose (SGLT2), inicialmente considerados medicamentos antihiperglicémicos inovadores, demonstraram benefícios significativos na melhoria dos marcadores metabólicos e na proteção renal e cardíaca em doentes com ou sem diabetes mellitus tipo 2. Estas vantagens cardiorenais inesperadas não podem ser atribuídas exclusivamente ao controle glicémico melhorado. Dados recentes sugerem que a reprogramação metabólica desempenha um papel no desenvolvimento de doenças metabólicas cardiorenais.
Apesar da eficácia dos inibidores do SGLT2 no tratamento de comorbilidades associadas à doença renal crónica (DRC) em adultos, o seu uso na população pediátrica aguarda validação. O desafio na DRC pediátrica reside no desequilíbrio entre as necessidades metabólicas da criança em crescimento e a capacidade funcional diminuída do rim em falência. Face à expectativa de vida prolongada da população pediátrica, é fundamental o desenvolvimento de estratégias dirigidas a fatores modificáveis na progressão da DRC.
Os inibidores do SGLT2 surgem como candidatos inovadores para o tratamento da DRC em crianças. Ao melhorar a adaptação hemodinâmica renal e mitigar as complicações gerais da DRC, estes agentes afiguram-se como uma potencial nova abordagem terapêutica para doentes pediátricos. Esta revisão incidirá no entendimento atual de como os inibidores do SGLT2 podem conferir proteção cardiorrenal.
Downloads
Referências
Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl (2011). 2022;12(1):7-11. doi: 10.1016/j.kisu.2021.11.003. Epub 2022 Mar 18. PMID: 35529086; PMCID: PMC9073222.
Kidney Disease: Improving Global Outcomes Work Group. KDIGO Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2012;2013(3):1–150.
Centers for Disease Control and Prevention. Chronic kidney disease in the United States, 2021. https://www.cdc.gov/kidneydisease/publications-resources/ckd-national-facts.html.
Mende CW. Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape. Adv Ther. 2022;39(1):148-64. doi: https://doi.org/10.1007/s12325-021-01994-2. Epub 2021 Nov 30. PMID: 34846711; PMCID: PMC8799531.
Di Costanzo A, Esposito G, Indolfi C, Spaccarotella CAM. SGLT2 Inhibitors: A New Therapeutical Strategy to Improve Clinical Outcomes in Patients with Chronic Kidney Diseases. Int. J. Mol. Sci. 2023, 24, 8732. https://doi.org/10.3390/ijms24108732.
Zinman B, Wanner C, Lachin J M, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 2015; 373: 2117–28.
McMurray J J V, Solomon S D, Inzucchi S E, Køber L, Kosiborod M N, Martinez F A, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med. 2019;381: 1995–2008.
Packer M, Anker S D, Butler J, Filippatos G, Pocock S J, Carson P, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N. Engl. J. Med. 2020; 383: 1413–24.
Anker S D, Butler J, Filippatos G, Ferreira J P, Bocchi E, Böhm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N. Engl. J. Med. 2021; 385: 1451–61.
Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, Bekiari E, et al. Sodium–glucose cotransporter 2 inhibitors for type 2 diabetes: A systematic review and meta-analysis. Ann. Intern. Med. 2013;159:262–274.
DeFronzo R A, Norton L, Abdul-Ghani M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat. Rev. Nephrol. 2017;13:11–26.
Škrtić M, Cherney D Z. Sodium–glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy. Curr. Opin. Nephrol. Hypertens. 2015;24:96–103.
Alshnbari AS, Millar SA, O’sullivan SE, Idris I. Effect of Sodium-Glucose Cotransporter-2 Inhibitors on Endothelial Function: A Systematic Review of Preclinical Studies. Diabetes Ther. 2020; 11:1947–1964.
Lee T M, Chang N C, Lin S Z. Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free. Radic. Biol. Med. 2017;104:298–310.
Takagi S, Li J, Takagaki Y, Kitada M, Nitta K, Takasu T, et al. Ipragliflozin improves mitochondrial abnormalities in renal tubules induced by a high-fat diet. J. Diabetes Investig. 2018; 9: 1025–1032.
Alicic R Z, Rooney M T, Tuttle K R. Diabetic kidney disease: challenges, progress, and possibilities. CJASN. 2017;12:2032–2045.
Vistisen D, Andersen G S, Hulman A, Persson F, Rossing P, Jørgensen M E. Progressive decline in estimated glomerular filtration rate in patients with diabetes after moderate loss in kidney function—even without albuminuria. Diabetes Care. 2019;42:1886–1894.
Gheith O, Farouk N, Nampoory N, Halim MA, Al-Otaibi T. Diabetic kidney disease: world wide difference of prevalence and risk factors. J Nephropharmacol. 2016;5:49–56.
Jitraknatee J, Ruengorn C, Nochaiwong S. Prevalence and risk factors of chronic kidney disease among type 2 diabetes patients: a cross-sectional study in primary care practice. Sci Rep. 2020;10:6205.
Jabbour S A, Frías J P, Hardy E, Ahmed A, Wang H, Öhman P, et al. Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial. Diabetes Care. 2018 Oct;41(10):2136-2146. doi: https://doi.org/10.2337/dc18-0680. Epub 2018 Aug 6. PMID: 30082326; PMCID: PMC6150435.
McCrimmon R J, Catarig A M, Frias J P, Lausvig N L, le Roux C W, Thielke D, et al. Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial. Diabetologia. 2020 Mar;63(3):473-485. doi: https://doi.org/10.1007/s00125-019-05065-8. Epub 2020 Jan 2. PMID: 31897524; PMCID: PMC6997246.
Rodbard H W, Rosenstock J, Canani L H, Deerochanawong C, Gumprecht J, Lindberg SØ, et al. PIONEER 2 Investigators. Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial. Diabetes Care. 2019 Dec;42(12):2272-2281. doi: https://doi.org/10.2337/dc19-0883. Epub 2019 Sep 17. PMID: 31530666.
Zinman B, Wanner C, Lachin J M, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373:2117–2128.
Wanner C, Inzucchi S E, Lachin J M, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016; 375:323–334.
Wiviott S D, Raz I, Bonaca M P, Mosenzon O, Kato E T, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019; 380:347–357.
Mosenzon O, Wiviott S D, Cahn A, Rozenberg A, Yanuv I, Goodrich E L, et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol. 2019;7:606–617.
Neal B, Perkovic V, Mahaffey K W, de Zeeuw D, Fulcher G, Erondu N, et al. CANVAS Program Collaborative Group: canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl JMed. 2017;377:644–657.
Perkovic V, Jardine M J, Neal B, Bompoint S, Heerspink H J L, Charytan DM, et al. CREDENCE Trial Investigators: canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295–2306.
Oshima M, Neuen B L, Li J W, Perkovic V, Charytan D M, de Zeeuw D, et al. Early change in albuminuria with canagliflozin predicts kidney and cardiovascular outcomes: a post hoc analysis from the CREDENCE trial. J Am Soc Nephrol. 2020;31:2925–2936.
Podestà M A, Sabiu G, Galassi A, Ciceri P, Cozzolino M. SGLT2 Inhibitors in Diabetic and Non-Diabetic Chronic Kidney Disease. Biomedicines. 2023 Jan 19;11(2):279. doi: https://doi.org/10.3390/biomedicines11020279. PMID: 36830815; PMCID: PMC9953060.
Gao Y M, Feng S T, Wen Y, Tang T T, Wang B, Liu B C. Cardiorenal Protection of SGLT2 Inhibitors—Perspectives from Metabolic Reprogramming. eBioMedicine. 2022;83:104215. doi: https://doi.org/10.1016/j.ebiom.2022.104215.
Palmer B F, Clegg D J. Kidney-Protective Effects of SGLT2 Inhibitors. Clin. J. Am. Soc. Nephrol. 2022 doi: https://doi.org/10.2215/CJN.09380822. online ahead of print .
Heerspink H J L, Stefánsson B V, Correa-Rotter R, Chertow G M, Greene T, Hou F F, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N. Engl. J. Med. 2020;383:1436–1446. doi: https://doi.org/10.1056/NEJMoa2024816.
McMurray J J V, Solomon S D, Inzucchi S E, Køber L, Kosiborod M N, Martinez F A, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N. Engl. J. Med. 2019;381:1995–2008. doi: https://doi.org/10.1056/NEJMoa1911303.
Jhund P S, Solomon S D, Docherty K F, Heerspink H J L, Anand I S, Böhm M, et al. Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients with Heart Failure With Reduced Ejection Fraction. Circulation. 2021;143:298–309.doi: https://doi.org/10.1161/CIRCULATIONAHA.120.050391.
Packer M, Anker S D, Butler J, Filippatos G, Pocock S J, Carson P, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N. Engl. J. Med. 2020;383:1413–1424. doi: https://doi.org/10.1056/NEJMoa2022190.
Packer M, Anker S D, Butler J, Filippatos G, Pocock S J, Carson P, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N. Engl. J. Med. 2020;383:1413–1424. doi: https://doi.org/10.1056/NEJMoa2022190.
The EMPA-KIDNEY Collaborative Group Empagliflozin in Patients with Chronic Kidney Disease. N. Engl. J. Med. 2022;388:117–127. doi: https://doi.org/10.1056/NEJMoa2204233.
Choi H, Nguyen LA, Wan J, Milani H, McGill K, Park J. Adverse Events of Sodium-Glucose Cotransporter-2 Inhibitors in Chronic Kidney Disease: A Retrospective Chart Review. Perm J. 2021 May;25:20.242. doi: https://doi.org/10.7812/TPP/20.242. PMID: 33970086; PMCID: PMC8784046.
Bailey C J, Day C, Bellary S. Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease. Curr Diab Rep. 2022 Jan;22(1):39-52. doi: https://doi.org/10.1007/s11892-021-01442-z. Epub 2022 Feb 3. PMID: 35113333; PMCID: PMC8888485.
Talha K M, Anker S D, Butler J. SGLT-2 Inhibitors in Heart Failure: A Review of Current Evidence. Int J Heart Fail. 2023 Mar 13;5(2):82-90. doi: https://doi.org/10.36628/ijhf.2022.0030. PMID: 37180562; PMCID: PMC10172076.
Shivakumar O, Sattar N, Wheeler DC. Sodium-glucose cotransporter 2 inhibitor effects on cardiovascular outcomes in chronic kidney disease. Nephrol Dial Transplant. 2020 Jan 1;35(Suppl 1):i43-i47. doi: https://doi.org/10.1093/ndt/gfz292. PMID: 32003831; PMCID: PMC6993195.
Zaccardi F, Webb D R, Htike Z Z, Youssef D, Khunti K, Davies M J. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes Metab. 2016;18:783–794.
Yang L, Zhang L, He H, Zhang M, An Z. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in east Asians with type 2 diabetes: a systematic review and meta-analysis. Diabetes Ther. 2019;10:1921–1934.
Yang Y, Zhao C, Ye Y, Yu M, Qu X. Prospect of sodium–glucose co-transporter 2 inhibitors combined with insulin for the treatment of type 2 diabetes. Front Endocrinol. 2020;10:3389. doi: https://doi.org/10.3389/fendo.2020.00190.
Chen J, Fan F, Wang J Y Long Y, Gao C L, Stanton R C, Xu Y. The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysis. Sci Rep. 2017;7:44128.
Taylor S I, Blau Jenny E, Rother K I. SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab. 2015;100:2849–52.
Laffel L M, Danne T, Klingensmith G J, Tamborlane W V, Willi S, Zeitler P, et al. DINAMO Study Group. Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial. Lancet Diabetes Endocrinol. 2023 Mar;11(3):169-181. doi: https://doi.org/10.1016/S2213-8587(22)00387-4. Epub 2023 Feb 1. PMID: 36738751.
Tamborlane W V, Laffel L M, Shehadeh N, Isganaitis E, Van Name M, Ratnayake J, et al. Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study. Lancet Diabetes Endocrinol. 2022 May;10(5):341-350. doi: https://doi.org/10.1016/S2213-8587(22)00052-3. Epub 2022 Apr 1. PMID: 35378069.
Liu J, Cui J, Fang X, Chen J, Yan W, Shen Q, et al. Efficacy and Safety of Dapagliflozin in Children With Inherited Proteinuric Kidney Disease: A Pilot Study. Kidney Int Rep. 2021 Dec 21;7(3):638-641. https://doi.org/doi: 10.1016/j.ekir.2021.12.019. PMID: 35257077; PMCID: PMC8897303.
Marinkovic-Radosevic J, Cigrovski Berkovic M, Kruezi E, Bilic-Curcic I, Mrzljak A. Exploring new treatment options for polycystic ovary syndrome: Review of a novel antidiabetic agent SGLT2 inhibitor. World J Diabetes. 2021 Jul 15;12(7):932-938. doi: https://doi.org/10.4239/wjd.v12.i7.932. PMID: 34326946; PMCID: PMC8311482.
Androutsakos T, Nasiri-Ansari N, Bakasis AD, Kyrou I, Efstathopoulos E, Randeva HS, et al. SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection. Int J Mol Sci. 2022 Mar 13;23(6):3107. doi: https://doi.org/10.3390/ijms23063107. PMID: 35328527; PMCID: PMC8953901.
Butts R, Nandi D, Hong B, Lorts A, Spinner J. SGLT2 Inhibitor Use in Pediatric Heart Failure. The Journal of Heart and Lung Transplantation. 2023; 42(4):S479.
Cirillo L, Ravaglia F, Errichiello C, Anders HJ, Romagnani P, Becherucci F. Expectations in children with glomerular diseases from SGLT2 inhibitors. Pediatr Nephrol. 2022 Dec;37(12):2997-3008. doi: https://doi.org/10.1007/s00467-022-05504-6. Epub 2022 Mar 14. PMID: 35286452.
Downloads
Publicado
Como Citar
Edição
Secção
Licença
Direitos de Autor (c) 2024 Joana Freitas
Este trabalho encontra-se publicado com a Creative Commons Atribuição-NãoComercial 4.0.
Copyright e Direitos dos Autores
Todos os artigos publicados na Revista Nascer e Crescer – Birth and Growth Medical Journal são de acesso aberto e cumprem os requisitos das agências de financiamento ou instituições académicas. Relativamente à utilização por terceiros a Nascer e Crescer – Birth and Growth Medical Journal rege-se pelos termos da licença Creative Commons "Atribuição - Uso Não-Comercial - (CC-BY-NC)"".
É da responsabilidade do autor obter permissão para reproduzir figuras, tabelas, etc. de outras publicações.
Juntamente com a submissão do artigo, os autores devem enviar a Declaração de conflito de interesses e formulário de autoria. Será enviado um e-mail ao autor correspondente, confirmando a receção do manuscrito.
Os autores ficam autorizados a disponibilizar os seus artigos em repositórios das suas instituições de origem, desde que mencionem sempre onde foram publicados e de acordo com a licença Creative Commons.
